Trial site
AHEPA University General Hospital of Thessaloniki
Thessaloniki, 546 36, GreeceNot linked to an institution yet
- 11running trials
- 2closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 21 trial
- Status
- Active, not recruiting5 trials
- Recruiting4 trials
- Completed2 trials
- Not yet recruiting2 trials
- Lead sponsor
- Eli Lilly and Company4 trials
- Takeda2 trials
- argenx1 trial
- IDEAYA Biosciences1 trial
- Infectopharm Arzneimittel GmbH1 trial
- and 4 more
Running trials
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450· Phase 2· Takeda· Source
Contact: Theodoros Karapanayiotides (principal investigator)
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190· Phase 3· IDEAYA Biosciences· Source
Contact: Konstantinos Boboridis, MD Principal Investigator
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170· argenx· Source
Contact: Marianthi Arnaoutoglou, MD
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318· Janssen-Cilag Ltd.· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951· Infectopharm Arzneimittel GmbH· Source
Contact: Aikaterini Efthimiou, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error